Lexeo Therapeutics Inc

Earnings data Q3 2023

Earnings data Q4 2024

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Lexeo Therapeutics, Inc. has filed to raise $126 million in an IPO, to support developing treatments for cardiovascular and Alzheimer's conditions. The company's lead candidate, LX2006, is in Phase 1/2 clinical trials for Friedreich's ataxia, with interim data expected in mid-2024. Lexeo is pursuing high-risk treatment areas, but faces legal risks and a challenging post-IPO environment for biopharma companies.

Lexeo Therapeutics Proposes Terms For $126 Million IPO

Lexeo Therapeutics, Inc. has filed for a $100 million IPO to develop treatments for cardiovascular and Alzheimer's conditions, although the final figure may differ. The company's lead candidate, LX2006, is currently in Phase 1/2 clinical trials for treating Friedreich's ataxia. The market opportunity for the conditions Lexeo is targeting is substantial and expected to grow in the coming years.

Lexeo Therapeutics Starts $100 Million U.S. IPO Effort

News for Lexeo Therapeutics Inc Stock (LXEO)